Associate Professor Alexander Guminski

Associate Professor
Medicine, Northern Clinical School

Telephone 02 99265020
Fax 02 99064150

Map

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Liniker, E., Menzies, A., Kong, B., Cooper, A., Ramanujam, S., Lo, S., Kefford, R., Fogarty, G., Guminski, A., Wang, T., Carlino, M., Hong, A., Long, G. (2016). Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. OncoImmunology, 5(9), 1-7. [More Information]
  • Pulvirenti, T., Hong, A., Clements, A., Forstner, D., Suchowersky, A., Guminski, A., McNeil, C., Hersey, P., Fogarty, G., Kefford, R., Long, G., Wang, T. (2016). Acute Radiation Skin Toxicity Associated With BRAF Inhibitors. Journal of Clinical Oncology, 34(3), e17-e20. [More Information]
  • Ahn, M., D'Cruz, A., Vermorken, J., Chen, J., Chitapanarux, I., Dang, H., Guminski, A., Kannarunimit, D., Lin, T., Ng, W., et al (2016). Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review. Oral Oncology, 53, 10-16. [More Information]
  • Johnson, D., Sullivan, R., Ott, P., Carlino, M., Khushalani, N., Ye, F., Guminski, A., Puzanov, I., Lawrence, D., Buchbinder, E., Menzies, A., Long, G., et al (2016). Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncology, 2(2), 234-240. [More Information]
  • Kong, B., Menzies, A., Saunders, C., Liniker, E., Ramanujam, S., Guminski, A., Kefford, R., Long, G., Carlino, M. (2016). Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy. Pigment Cell & Melanoma Research, 29(5), 572-577. [More Information]
  • Charles (nee Slaviero), K., Harris, B., Haddad, C., Clarke, S., Guminski, A., Stevens, M., Dodds, T., Gill, A., Back, M., Veivers, D., Eade, T. (2016). Systemic inflammation is an independent predictive marker of clinical outcomes in mucosal squamous cell carcinoma of the head and neck in oropharyngeal and nonoropharyngeal patients. BMC Cancer, 16(1), 1-13. [More Information]
  • Menzies, A., Wilmott, J., Drummond, M., Lo, S., Lyle, M., Chan, M., Thompson, J., Guminski, A., Carlino, M., Scolyer, R., Kefford, R., Long, G. (2015). Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Cancer, 121(21), 3826-3835. [More Information]
  • Haddad, C., Guo, L., Clarke, S., Guminski, A., Back, M., Eade, T. (2015). Neutrophil-to-lymphocyte ratio in head and neck cancer. Journal of Medical Imaging and Radiation Oncology, 59(4), 514-519. [More Information]
  • Porceddu, S., Veness, M., Guminski, A. (2015). Nonmelanoma Cutaneous Head and Neck Cancer and Merkel Cell Carcinoma: Current Concepts, Advances,and Controversies. Journal of Clinical Oncology, 33(29), 3338-3345. [More Information]
  • Menzies, A., Atkinson, V., Brown, M., Carlino, M., Cebon, J., Guminski, A., Kefford, R., Long, G., McArthur, G., McNeil, C., et al (2015). Sentinel node biopsy for melanoma: The medical oncology perspective. Australian Family Physician, 44(12), 875-876.
  • Migden, M., Guminski, A., Gutzmer, R., Dirix, L., Lewis, K., Combermale, P., Herd, R., Herd, R., Kudchadkar, R., Trefzer, U., et al (2015). Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. The Lancet Oncology, 16(6), 716-728. [More Information]
  • Lodh, S., Maher, R., Guminski, A. (2014). Intra-arterial infusion and chemo-embolization for melanoma liver metastases. Journal of Surgical Oncology, 109(4), 376-382. [More Information]
  • Chan, M., Haydu, L., Menzies, A., Azer, M., Klein, O., Lyle, M., Clements, A., Guminski, A., Kefford, R., Long, G. (2014). The nature and management of metastatic melanoma after progression on braf inhibitors: Effects of extended BRAF inhibition. Cancer, 120(20), 3142-3153. [More Information]
  • Fogarty, G., Guminski, A., Shannon, K. (2013). How important is multidisciplinary treatment of melanoma metastases? Expert Review of Dermatology, 8(4), 339-341. [More Information]
  • Johnston, M., Guo, L., Back, M., Guminski, A., Lee, A., Hanna, C., Veivers, D., Wignall, A., Eade, T. (2013). Intensity-modulated radiotherapy using simultaneous-integrated boost for definitive treatment of locally advanced mucosal head and neck cancer: Outcomes from a single-institution series. Journal of Medical Imaging and Radiation Oncology, 57(3), 356-363. [More Information]
  • Guminski, A. (2012). New systemic treatment options for advanced basal cell carcinoma. Cancer Forum, 36(3), 138-141.
  • Saunders, N., Simpson, F., Thompson, E., Hill, M., Endo-Munoz, L., Leggatt, G., Minchin, R., Guminski, A. (2012). Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Molecular Medicine, 4(8), 675-684. [More Information]
  • Khasraw, M., Atkinson, C., Van der Saag, D., Pavlakis, N., Guminski, A. (2009). Cardiac toxicity from sunitinib: Do we need to be more vigilant? Asia-Pacific Journal of Clinical Oncology, 5(4), 217-218. [More Information]
  • Guminski, A., Thompson, J. (2009). Predicting response to IL-2 therapy for metastatic melanoma. Expert Review of Anticancer Therapy, 9(11), 1571-1575. [More Information]
  • Scurr, L., Guminski, A., Chiew, Y., Balleine, R., Sharma, R., Lei, Y., Pryor, K., Wain, G., Brand, A., Byth, K., Kennedy, C., Rizos, H., Harnett, P., deFazio, A. (2008). Ankyrin Repeat Domain 1, ANKRD1, a Novel Determinant of Cisplatin Sensitivity Expressed in Ovarian Cancer. Clinical Cancer Research, 14(21), 6924-6932. [More Information]
  • Guminski, A., Balleine, R., Chiew, Y., Webster, L., Tapner, M., Farrell, G., Harnett, P., deFazio, A. (2006). MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecologic Oncology, 100(2), 239-246. [More Information]
  • Guminski, A., Harnett, P., deFazio, A. (2001). Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line - a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia. Cancer Chemotherapy and Pharmacology, 48(3), 229-234.
  • Guminski, A., deFazio, A., Harnett, P. (2001). New genetics and cancer chemotherapy. Today's Life Science (Australia), 13(2), 36-40.

Patents

  • deFazio, A., Harnett, P., Guminski, A. (2005). Patent Families: Determinants of sensitivity to chemotherapeutic agents. Patent No. 2005316200.

2016

  • Liniker, E., Menzies, A., Kong, B., Cooper, A., Ramanujam, S., Lo, S., Kefford, R., Fogarty, G., Guminski, A., Wang, T., Carlino, M., Hong, A., Long, G. (2016). Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. OncoImmunology, 5(9), 1-7. [More Information]
  • Pulvirenti, T., Hong, A., Clements, A., Forstner, D., Suchowersky, A., Guminski, A., McNeil, C., Hersey, P., Fogarty, G., Kefford, R., Long, G., Wang, T. (2016). Acute Radiation Skin Toxicity Associated With BRAF Inhibitors. Journal of Clinical Oncology, 34(3), e17-e20. [More Information]
  • Ahn, M., D'Cruz, A., Vermorken, J., Chen, J., Chitapanarux, I., Dang, H., Guminski, A., Kannarunimit, D., Lin, T., Ng, W., et al (2016). Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review. Oral Oncology, 53, 10-16. [More Information]
  • Johnson, D., Sullivan, R., Ott, P., Carlino, M., Khushalani, N., Ye, F., Guminski, A., Puzanov, I., Lawrence, D., Buchbinder, E., Menzies, A., Long, G., et al (2016). Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncology, 2(2), 234-240. [More Information]
  • Kong, B., Menzies, A., Saunders, C., Liniker, E., Ramanujam, S., Guminski, A., Kefford, R., Long, G., Carlino, M. (2016). Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy. Pigment Cell & Melanoma Research, 29(5), 572-577. [More Information]
  • Charles (nee Slaviero), K., Harris, B., Haddad, C., Clarke, S., Guminski, A., Stevens, M., Dodds, T., Gill, A., Back, M., Veivers, D., Eade, T. (2016). Systemic inflammation is an independent predictive marker of clinical outcomes in mucosal squamous cell carcinoma of the head and neck in oropharyngeal and nonoropharyngeal patients. BMC Cancer, 16(1), 1-13. [More Information]

2015

  • Menzies, A., Wilmott, J., Drummond, M., Lo, S., Lyle, M., Chan, M., Thompson, J., Guminski, A., Carlino, M., Scolyer, R., Kefford, R., Long, G. (2015). Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Cancer, 121(21), 3826-3835. [More Information]
  • Haddad, C., Guo, L., Clarke, S., Guminski, A., Back, M., Eade, T. (2015). Neutrophil-to-lymphocyte ratio in head and neck cancer. Journal of Medical Imaging and Radiation Oncology, 59(4), 514-519. [More Information]
  • Porceddu, S., Veness, M., Guminski, A. (2015). Nonmelanoma Cutaneous Head and Neck Cancer and Merkel Cell Carcinoma: Current Concepts, Advances,and Controversies. Journal of Clinical Oncology, 33(29), 3338-3345. [More Information]
  • Menzies, A., Atkinson, V., Brown, M., Carlino, M., Cebon, J., Guminski, A., Kefford, R., Long, G., McArthur, G., McNeil, C., et al (2015). Sentinel node biopsy for melanoma: The medical oncology perspective. Australian Family Physician, 44(12), 875-876.
  • Migden, M., Guminski, A., Gutzmer, R., Dirix, L., Lewis, K., Combermale, P., Herd, R., Herd, R., Kudchadkar, R., Trefzer, U., et al (2015). Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. The Lancet Oncology, 16(6), 716-728. [More Information]

2014

  • Lodh, S., Maher, R., Guminski, A. (2014). Intra-arterial infusion and chemo-embolization for melanoma liver metastases. Journal of Surgical Oncology, 109(4), 376-382. [More Information]
  • Chan, M., Haydu, L., Menzies, A., Azer, M., Klein, O., Lyle, M., Clements, A., Guminski, A., Kefford, R., Long, G. (2014). The nature and management of metastatic melanoma after progression on braf inhibitors: Effects of extended BRAF inhibition. Cancer, 120(20), 3142-3153. [More Information]

2013

  • Fogarty, G., Guminski, A., Shannon, K. (2013). How important is multidisciplinary treatment of melanoma metastases? Expert Review of Dermatology, 8(4), 339-341. [More Information]
  • Johnston, M., Guo, L., Back, M., Guminski, A., Lee, A., Hanna, C., Veivers, D., Wignall, A., Eade, T. (2013). Intensity-modulated radiotherapy using simultaneous-integrated boost for definitive treatment of locally advanced mucosal head and neck cancer: Outcomes from a single-institution series. Journal of Medical Imaging and Radiation Oncology, 57(3), 356-363. [More Information]

2012

  • Guminski, A. (2012). New systemic treatment options for advanced basal cell carcinoma. Cancer Forum, 36(3), 138-141.
  • Saunders, N., Simpson, F., Thompson, E., Hill, M., Endo-Munoz, L., Leggatt, G., Minchin, R., Guminski, A. (2012). Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Molecular Medicine, 4(8), 675-684. [More Information]

2009

  • Khasraw, M., Atkinson, C., Van der Saag, D., Pavlakis, N., Guminski, A. (2009). Cardiac toxicity from sunitinib: Do we need to be more vigilant? Asia-Pacific Journal of Clinical Oncology, 5(4), 217-218. [More Information]
  • Guminski, A., Thompson, J. (2009). Predicting response to IL-2 therapy for metastatic melanoma. Expert Review of Anticancer Therapy, 9(11), 1571-1575. [More Information]

2008

  • Scurr, L., Guminski, A., Chiew, Y., Balleine, R., Sharma, R., Lei, Y., Pryor, K., Wain, G., Brand, A., Byth, K., Kennedy, C., Rizos, H., Harnett, P., deFazio, A. (2008). Ankyrin Repeat Domain 1, ANKRD1, a Novel Determinant of Cisplatin Sensitivity Expressed in Ovarian Cancer. Clinical Cancer Research, 14(21), 6924-6932. [More Information]

2006

  • Guminski, A., Balleine, R., Chiew, Y., Webster, L., Tapner, M., Farrell, G., Harnett, P., deFazio, A. (2006). MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecologic Oncology, 100(2), 239-246. [More Information]

2005

  • deFazio, A., Harnett, P., Guminski, A. (2005). Patent Families: Determinants of sensitivity to chemotherapeutic agents. Patent No. 2005316200.

2001

  • Guminski, A., Harnett, P., deFazio, A. (2001). Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line - a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia. Cancer Chemotherapy and Pharmacology, 48(3), 229-234.
  • Guminski, A., deFazio, A., Harnett, P. (2001). New genetics and cancer chemotherapy. Today's Life Science (Australia), 13(2), 36-40.

To update your profile click here. For support on your academic profile contact .